Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12

Background: Ovarian cancer (OC) is gynecologic cancer with the highest mortality rate. It is estimated that 13–17% of ovarian cancers are due to heritable mutations in BRCA1 and BRCA2. The BRCA1 (BRCA1-Del ex9-12) Mexican founder mutation is responsible for 28–35% of the cases with ovarian cancer. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallardo-Rincón, Dolores, Montes-Servín, Edgar, Alamilla-García, Gabriela, Montes-Servín, Elizabeth, Bahena-González, Antonio, Cetina-Pérez, Lucely, Morales Vásquez, Flavia, Cano-Blanco, Claudia, Coronel-Martínez, Jaime, González-Ibarra, Ernesto, Espinosa-Romero, Raquel, María Alvarez-Gómez, Rosa, Pedroza-Torres, Abraham, Castro-Eguiluz, Denisse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207274/
https://www.ncbi.nlm.nih.gov/pubmed/35734436
http://dx.doi.org/10.3389/fgene.2022.863956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207274/
https://www.ncbi.nlm.nih.gov/pubmed/35734436
http://dx.doi.org/10.3389/fgene.2022.863956

Ejemplares similares